1	Influenza vaccination allocation in tropical settings under constrained
2	resources
3	
4	
5	Joseph L Servadio ^{1,2*} , Marc Choisy ^{3,4} , Pham Quang Thai ^{5,6} , Maciej F Boni ^{1,2,4}
6	
7	
8	1 Center for Infectious Disease Dynamics and Department of Biology, Pennsylvania State
9	University, University Park, PA, United States
10	² Department of Biology, Temple University, Philadelphia, PA, United States
11	³ Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam
12	⁴ Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine,
13	University of Oxford, Oxford, United Kingdom
14	⁵ National Institute of Hygiene and Epidemiology, Hanoi, Vietnam
15	⁶ School of Preventative Medicine and Public Health, Hanoi Medical University, Hanoi,
16	Vietnam
17	
18	*corresponding author: Joseph L Servadio, Department of Biology, Temple University,
19	Philadelphia, PA, United States. jlservadio@temple.edu
20	
21	
22	Keywords: Influenza; Vaccination; Allocation; Vaccine Supply; Mathematical Model
23	

24 Abstract

25

26 Influenza virus seasonality, synchronicity, and vaccine supply differ substantially between 27 temperate and tropical settings, and optimal vaccination strategy may differ on this basis. 28 Most national vaccine recommendations focus on high-risk groups, elderly populations, and 29 healthcare workers despite previous analyses demonstrating broad benefits to vaccinating 30 younger high-contact age groups. Here, we parameterized an age-structured non-seasonal 31 asynchronous epidemiological model of influenza virus transmission for a tropical low-32 income setting. We evaluated timing and age allocation of vaccines across vaccine supplies ranging from 10% to 90% using decade-based age groups. Year-round vaccination was 33 34 beneficial when comparing to vaccination strategies focused on a particular time of year. 35 When targeting a single age-group for vaccine prioritization, maximum vaccine allocation 36 to the 10-19 high-contact age group minimized annual influenza mortality for all but one 37 vaccine supply. When evaluating across all possible age allocations, optimal strategies 38 always allocated a plurality of vaccines to school-age children (10-19). The converse however was not true as not all strategies allocating a plurality to children aged 10-19 39 40 minimized mortality. Allocating a high proportion of vaccine supply to the 10-19 age group 41 is necessary but not sufficient to minimize annual mortality as distribution of remaining 42 vaccine doses to other age groups also needs to be optimized. Strategies focusing on 43 indirect benefits (vaccinating children) showed higher variance in mortality outcomes than strategies focusing on direct benefits (vaccinating the elderly). However, the indirect benefit 44 45 approaches showed lower mean mortality and lower minimum mortality than vaccination 46 focused on the elderly.

48 Significance statement

49

50 Influenza exhibits strong annual seasonality in temperate countries, but less consistent and

- 51 predictable patterns in tropical countries. Many tropical countries are low-income
- 52 countries with low influenza vaccine coverage. Globally, influenza vaccines are
- recommended for elderly adults and vulnerable groups, though evidence has shown that
- 54 vaccinating school-age children is beneficial due to their high rates of social contact. Our
- 55 modeling study evaluated whether age-based vaccine allocations can effectively minimize
- 56 population influenza mortality in a tropical country with constrained resources and little
- 57 seasonality. Prioritizing school-aged children for vaccination minimized mortality, with
- 58 secondary emphasis on elderly adults. These benefits are most apparent under low vaccine
- 59 supplies and can inform most effective ways to develop or expand influenza vaccination
- 60 campaigns in low-income tropical settings.

62 Introduction

63

64 Influenza remains a persistent public health challenge globally causing up to 650,000 65 deaths annually [1]. It is present worldwide and prior to the emergence of SARS-CoV-2 was 66 the most deadly infectious disease in many high-income [2-4] and some lower-income 67 countries [5]. Morbidity and mortality from influenza can be mitigated through regular 68 administration of vaccines. In high-income countries (HICs), between 28% and 42% of 69 residents are vaccinated for influenza annually [6–8], primarily targeting elderly adults and 70 those with underlying health conditions [9] with the majority of vaccines given prior to the onset of the winter influenza season. Most lower and lower-middle income countries 71 72 (LMICs) have influenza vaccine coverage below 10% [10] with age/group targeting similar 73 to higher income countries and no specific annual timing for vaccination campaigns. 74 When introducing or increasing coverage of influenza vaccines in lower-income settings, 75 76 three major differences in influenza epidemiology to consider between HICs and LMICs are that LMICs have younger populations, irregular and unpredictable seasonality of influenza 77 (if they are tropical or sub-tropical), and lower vaccine supplies. Timing vaccination just 78 79 prior to an epidemic is important due to evidence of waning of vaccine-induced protection 80 over time [11,12], and optimizing age-specific allocation is critical for vaccine distribution 81 as influenza transmission as well as morbidity and mortality vary with age. Countries with 82 established influenza vaccination programs consistently encourage vaccination during a 83 particular time of year and seek to optimize vaccine recommendations based on age.

84 exposure, or vulnerability to maximize the vaccine rollout's mortality reductions. This

planning is of course predicated on sufficient supply and population willingness to bevaccinated.

87

Almost universally, emphasis is placed on vaccinating populations at highest risk of
exposure or severe outcomes, including healthcare workers, young children, and elderly
adults. This is seen across HICs and LMICs by promoting vaccination in particular high-risk
groups as part of a general voluntary vaccination approach [13–18]. Prioritization based on

advanced age or health status was likewise reflected in COVID-19 vaccination rollouts in 92 93 2021 [19,20]. However, compared to COVID-19, influenza has a shallower age-severity 94 curve and vaccination approaches can be more flexibly designed to target different age 95 groups based on both contact mixing and severity considerations. As an example, an 96 alternate strategy that focuses influenza vaccination on school-age children – a group with 97 high levels of in-group and out-group social contact – was followed in Japan in the 1970s 98 and 1980s, with some evidence of success in reducing nationwide influenza mortality [21]. 99 Additional research from the United Kingdom found it to be a cost-effective method of 100 reducing influenza mortality [22]. Other studies aiming to compare age-based vaccination 101 strategies for influenza have typically found that vaccinating school-age children is 102 advantageous due to their large contribution to transmission [23–29]. This choice between 103 focusing vaccination on high-risk groups versus high-contact groups is a classic question in 104 vaccine allocation for respiratory pathogens and depends strongly on overall transmission 105 rate, the age-structure of the population and social contacts, and the age-morbidity 106 association [30].

107

In this study, we parameterized an age-structured mathematical model of influenza 108 109 transmission to the asynchronous non-annual epidemiology of tropical influenza in 110 Vietnam, where influenza vaccination is currently being planned. Vietnam's high 111 population, inconsistency of influenza epidemic timing, and presence of both subtropical 112 and tropical climates make it a suitable case study where results may apply to other 113 subtropical and tropical countries, particularly within southeast Asia. We evaluated vaccine 114 allocations in this context to determine the optimal allocation of influenza vaccines to see if 115 this differs from recommendations typical in temperate high-income settings.

116

117 Results

118

119 The mathematical model developed in this study includes three (sub)types of influenza,

120 decade-based age groups, and compartments for those who received an influenza vaccine

121 (Supplemental text S1, Figure S1). Fifty parameterizations of this dynamic epidemiological

model of tropical influenza transmission were generated that achieved (1) sustained co-

123 circulation of three influenza (sub)types: influenza A/H1N1, influenza A/H3N2, and

- influenza B; (2) non-damped oscillation of all three subtypes; (3) no synchronicity or
- 125 phase-locking between any two subtypes; (4) stationary annual all-influenza attack rates
- between 15% and 35%; and (5) no clear dominance of any one subtype (Supplemental text
- 127 S1). These dynamics are based on a well-characterized tropical influenza time series from
- 128 Vietnam (4641 incidence data points over ten years). Across the fifty parameter scenarios,
- the median annual attack rate is 22.6% (IQR: 21.6-23.8%), and median annual mortality is
- 130 15,499 deaths (IQR: 14,816-16,427) in a population of 100 million, with 46.6% (IQR: 46.2 –
- 47.1) of deaths occurring in the 70+ age group and 30.9% (IQR: 30.8 31.0) occurring in
- the 60-69 age group. Adjusting for population, this is consistent with a relatively severe

influenza season in the United States. Figure 1 shows examples of the simulated influenza

- scenarios in which we evaluated vaccine timings and age allocations as well as distributions
- 135 of parameters among these 50 sets.



Figure 1. Model parameterizations epidemiologically consistent with observed influenza
dynamics in Vietnam. (a) Four example model incidence trajectories, with daily incidence
values for influenza A/H1N1, A/H3N2, and B over a ten-year period. The parameterizations
leading to these trajectories were used in modeling to evaluate effectiveness of vaccination
strategies. (b) Distributions of the parameters comprising these parameter sets.

- 144
- 145 Some evidence was found for a preferred time of year for vaccinating. Among vaccine
- 146 programs spanning four months, changing the starting month reduced mortality by
- 147 between 219 (1.6%) and 1,089 (32.4%) deaths per year across seven vaccine supplies.

Larger differences were seen under higher vaccine supplies. The starting month minimizing 148 149 mortality was January for all except one vaccine supply (40%), where February was the 150 starting month minimizing mortality (Figure S2). Implementing a year-round vaccination 151 strategy, however, led to the lowest average annual mortality; across vaccine supplies, a 152 year-round vaccine campaign led to 0 to 7% fewer deaths than the 4-month vaccination 153 campaign with lowest mortality. In all evaluated scenarios, increasing vaccine supply 154 proved substantially more influential in reducing influenza mortality compared to aiming 155 to vaccinate during a particular time of year.

156

157 When considering a single age-group prioritization scheme, our analysis shows benefits of 158 targeting school-age children for reducing influenza mortality among all age groups in a 159 population. Across different vaccine supplies, we allocated vaccines to a single age group 160 until full coverage was achieved; remaining vaccines were allocated proportionally across 161 the other seven age groups. For eight of the nine vaccine supplies, lowest population 162 mortality was achieved by prioritizing the 10-19 age group (Figure 2). Prioritizing the two 163 oldest age groups (60-69 and 70+) typically also led to higher reductions in mortality compared to other age group prioritizations, and prioritizing the 70+ age group produced 164 165 the lowest average annual mortality for a vaccine supply that covered 20% of the 166 population. Differences in mortality based on the age group prioritized is more pronounced 167 under lower vaccine supplies; compared to age-proportional vaccination, prioritizing the 168 10-19 age group leads to a reduction in mortality that ranges from 2.3% (20% supply) to 169 23.3% (60% supply). This is consistent with the well-known trade-off in respiratory 170 disease vaccine allocation where the two major approaches to reduce disease burden are 171 (1) reducing severity directly by vaccinating high-risk/vulnerable groups, and (2) reducing 172 severity indirectly by reducing overall incidence which is achieved by vaccinating high-173 contact groups.



175

Figure 2. Expected annual mortality from prioritizing ten-year age bands (e.g. "20s" or
"50s") for vaccination. Under varying vaccine supplies, one age group was vaccinated until
100% coverage was reached, and remaining doses were distributed proportionally to the
other seven age groups. Panel (a) shows eight black dots for the eight age-group
prioritizations and one red dot for age-proportional distribution. The red line indicates
mortality with no vaccination. Panel (b) shows zoomed-in and labeled mortality results for
better distinction across age groups.

183 184

185 Even though single-age prioritization is a natural point of focus and often a default strategy

186 considered in public health planning, allocating the vaccine supply to multiple key age

187 groups may achieve further reductions in burden. We evaluated precise vaccine allocations

- across the eight age groups 74,500 in total chosen to approximate a brute-force
- approach to covering all possible age-group coverage combinations via a modified Latin
- 190 Hypercube approach (see Methods and supplemental text S2). These evaluations show that
- a substantial lowering (up to a factor of 2.0) of mortality can occur when finding an optimal

192 allocation for a given vaccine supply compared to a nonoptimal allocation. Figure 3 shows 193 the distribution of annual mortality resulting from all tested allocations of vaccines for nine 194 vaccine supplies. Greater benefits of age-specific allocation, when comparing to distributing 195 vaccines proportionally across ages, are easily seen when vaccine supplies are low ($\leq 50\%$ 196 supply). When comparing allocations that primarily vaccinate school-aged children (10-19) 197 and the two oldest age groups (60+), primarily vaccinating younger children can lead to 198 lower mortality, but with a wider range of possible mortality values (Figure 3b). This is 199 seen further when examining the allocations that exclusively vaccinate either the two 200 voungest or two oldest age groups for a vaccine supply available for 10% of the population 201 (Figure 3c). Among the thirteen allocations exclusively vaccinating the oldest and youngest 202 age groups, the lowest mortality is seen in one of the allocations exclusively vaccinating the 203 two youngest age groups; however, all of the allocations exclusively vaccinating the oldest 204 age groups lead to close-to-optimal low mortality due to the low variance of mortality 205 outcomes when vaccination strategy aims for direct benefits over indirect benefits. 206



208

Figure 3. Mortality under various vaccine supplies and allocations. (a) Mortality among all 209 210 considered vaccine allocations (N = 74500) for vaccine supplies for 10-90% of the population. Red points within the violin plots represent mortality if vaccines are allocated 211 across age groups proportionally. (b) Mortality among the subsets of allocations 212 represented in (a) that reserve the largest portion of vaccines for the 10-19 age group 213 214 (blue) or two oldest age groups (orange). No vaccine allocations exist allocating a plurality of vaccines to the 60-69 or 70+ age groups when vaccine supply exceeds 40%. (c) Mortality 215 216 under a vaccine supply for 10% of the population that exclusively vaccinates the two 217 voungest age groups (left, blue) and two oldest age groups (right, orange). The percentage of vaccines allocated to the 0-9/10-19 age group as well as the percentage allocated to the 218 60-69/70+ age groups are indicated next to each point. 219 220

221

222 The vaccine allocations that best reduce mortality differ by vaccine supply, as shown in

- Figure 4. Under the lowest vaccine supplies, allocations that primarily focus on school-age
- children (10-19) were most effective, with some inclusion of elderly adults (70+) and adults
- of working age (20-39). These age groups represent those most likely to experience

influenza mortality and those who have high degrees of social mixing within the

population. Under more moderate vaccine supplies (available for 30-50% of the

population), primarily vaccinating individuals between 10 and 49, largely representing

- school-age children and working adults, proved most effective. For vaccine allocations
- 230 greater than 60%, vaccine allocations leading to the greatest reduction in mortality more
- closely resembled those proportional to the population age structure (Figure 4).
- 232



Figure 4. Optimal vaccine age-allocations across various vaccine supplies shown in panels A-I. In each panel, the light blue bar representing vaccine supply is shown next to the population age distribution, showing the relative sizes of the vaccine supply and population age groups. The ten blue/green bars on the right of each panel show the ten age allocations that minimize mortality, ranked from left to right by average annual total mortality. Annual mortality numbers for each allocation are shown at the top of each column. Blue age allocation boxes indicate vaccine coverage above 95% for that age group; age group

- coverage for green boxes corresponds to the color bar in panel J.
- 242
- 243
- 244 Prioritizing school-age children is necessary but not sufficient for minimizing mortality,
- 245 particularly at low vaccine supplies. Among the vaccine allocations that prioritize school-
- age children, the vaccine distribution among the remaining doses across the other seven
- 247 age groups can lead to notable differences in mortality. There are no straightforward
- 248 monotonic relationships between age-group vaccine allocation and population mortality as
- can be seen clearly in Figure 5. Allocations achieving high vaccine coverage in the 10-19 age
- 250 group need to also distribute adequate doses to adults 60+ to minimize mortality. This new
- finding on sufficiency of a certain age-group focus in vaccination programs along with the
- wider variance in mortality when prioritizing school aged children shows the importance
- 253 of proper planning for allocating the entire vaccine supply.
- 254
- 255



257

Figure 5. Vaccination coverages in two age groups (10-19, 70+) across all considered 258 allocations of two vaccine supplies (20%, 50%), ranked by average annual population 259 mortality. Red dots in each panel indicate the allocations with proportional vaccination 260 across all age groups. Top row: Average annual mortality for each allocation. Middle row: 261 Vaccination coverages for the 10-19 age group among the ranked allocations. The general 262 263 downward slope shows the importance of vaccinating this age group for reducing 264 population mortality, but the low rank of many allocations with high coverage for this age group with 20% supply (left) show that saturating this age group and leaving others 265 unvaccinated is not guaranteed to be optimal. Bottom row: Vaccination coverages for the 266 70+ age group among ranked allocations. Full results, across all vaccine supplies and all age 267 268 groups, are shown in Figure S3.

- 269
- 270
- 271 Our analyses assumed the effectiveness of influenza vaccines and duration of vaccine-
- 272 induced immunity consistent with previous literature [31–36]. We repeated our analyses

varying each of these to determine whether the vaccine allocations minimizing mortality 273 274 change with different effectiveness values or immune durations (full details in 275 Supplemental text S3). If vaccine effectiveness is reduced from 50% to 40% or 30%. 276 targeting elderly adults typically led to lowest annual mortality values, particularly when 277 vaccine supplies are lower. This suggests a new efficacy-dependent allocation that would 278 need to be validated: majority allocation to older age groups during strain-mismatch years 279 and majority allocation to younger age groups during other years. Under increased vaccine 280 effectiveness, prioritizing school-age children remained advantageous for minimizing 281 mortality (Figures S4 and S5). Similarly, reducing the assumed 9-month average duration of 282 immunity to 6 to 7 months shifted the optimum vaccination strategy to one that prioritizes 283 elderly adults while increasing immune duration in the model kept school-age children as 284 the key group for prioritization (Figures S6 and S7). We also examined changes in age 285 structure, comparing the age structures of Vietnam, the United States, and intermediate age 286 structures. The benefits of primarily vaccinating the 10-19 age group, particularly at low 287 vaccine supplies, were seen across all five age structures (Figures S8, S9), indicating that 288 age-structure differences in HICs and LMICs should not have a substantial effect on the choice of optimal vaccine policy. 289

290

291 Discussion

292

293 This study aimed to identify vaccine distribution strategies that most effectively reduce 294 annual mortality in the absence of annual seasonality. This absence of seasonality is most 295 typically seen in tropical countries, many of which are LMICs with currently low vaccine 296 coverage. We used influenza dynamics from Vietnam to inform a non-seasonal 297 asynchronous influenza model and evaluated various vaccine allocations under different 298 supply constraints, resembling the development or expansion of a national vaccine 299 program. A clear time of year was not identified that would most effectively reduce 300 influenza mortality, and age-structure difference between tropical and temperate settings 301 did not seem to influence vaccine policy choice. Age-based allocations that prioritize 302 school-aged children were most effective at reducing overall mortality, and benefits of 303 vaccinating working-age adults and elderly adults were also seen (Figure 4). The benefits of

prioritizing particular age groups are most prominent when vaccine supplies are low,
emphasizing their importance when first establishing a vaccine program. Under higher
vaccine supply, allocating vaccines proportionally across age groups is an adequate burden
reduction approach. Our finding of the advantages in prioritizing school-age children differs
from the typical recommendations that prioritize elderly adults but is consistent with
previous studies [24,25,37].

310

311 Strategies that led to the greatest reduction in mortality included vaccinating school-aged 312 children and elderly adults, the groups with the highest social mixing in the population 313 [38,39] and mortality risk [40,41], respectively. Children have also previously been found to 314 have higher observed influenza incidence [42]. The benefits of prioritizing these two 315 groups rather than allocating vaccines proportionally are greatest when considering the 316 lowest vaccine supply (available for 10% of the population). Vaccinating working-age 317 adults, particularly those aged 30-39, was also beneficial under lower vaccine supplies, 318 which is supported by previous literature [24]. The benefits of prioritizing school-aged 319 children depended on factors such as vaccine supply, vaccine effectiveness, and average 320 duration of vaccine-inferred immunity. Decreasing vaccine effectiveness or duration of 321 vaccine-induced immunity, led to strategies that favor primarily vaccinating elderly adults 322 being the most effective (Figures S4-S7). Because vaccine effectiveness can fluctuate across 323 years, it is possible that the optimal age-based strategies will vary across years.

324

325 The World Health Organization's position on influenza vaccination emphasizes annual 326 vaccination for elderly adults because they are at the highest risk of death [43,44]. Some 327 previous studies regarding vaccine strategies have also found that prioritizing elderly 328 adults is most beneficial for both influenza [45] and COVID-19 [46]. Other studies, however, 329 have considered the benefits of prioritizing school-age children based on their high level of 330 social mixing both within and outside of their age group [47]. A study from the United 331 Kingdom found vaccinating children to be of greater overall benefit, with reallocating 332 vaccines to elderly adults being less cost effective [22]. The decision in practice to not focus 333 vaccination on school-age children may result from increased barriers to uptake such as

inconvenience, complacency, unawareness of the magnitude of benefit, or perceptions ofinfluenza-associated risk [48,49].

336

337 Vaccine supply – a variable that is not considered in optimal allocation problems in 338 wealthier countries – plays a critical role in determining optimal allocation in a resource-339 constrained setting. We focused on supply to consider the development of a vaccine 340 program in a tropical country that currently does not currently achieve high vaccination 341 coverage, such as Vietnam. Most previous studies examining effective ways to vaccinate a 342 population for influenza or other respiratory viruses primarily investigate population 343 coverage [50,51] or distribution of a fixed supply [25,52], with some giving attention to 344 vaccine supply [24,46,53]. By considering how to allocate among nine vaccine supplies, our 345 results are more applicable to policy makers and health professionals, showing how 346 optimal allocations can differ across supply levels (Figure 4). We assume perfect adherence 347 to each allocation. In practice however, some allocations may be less feasible due to age-348 differentiated willingness to be vaccinated or access to vaccination (such as ease of 349 vaccinating in a school setting compared to visiting a clinic for vaccination).

350

351 In the context of an existing, but limited, vaccine program, an open question in optimal 352 vaccine allocations is how to most effectively use an expanding vaccine supply. By 353 examining a broad range of vaccine supplies, we showed how optimal allocations change 354 when establishing a small vaccine program and then when expanding a current program. 355 When developing a program in a tropical country, our results support primarily allocating a 356 very limited supply to school-age children and elderly adults. Under more moderate 357 supplies, it is beneficial to include working-age adults. At the highest supply levels, it is 358 sufficient to vaccinate proportionally across age groups, with less benefits from opting for 359 an age-based allocation.

360

Our model accounts for age-based influenza dynamics but does not consider differences
across locations. These can include asynchronous influenza epidemics among northern,
central, and southern Vietnam [54] or differences in vaccine coverage between urban and
rural communities [55]. Our model also only considers age for both hospitalization and

365 mortality risk as well as for vaccine priorities. Differences in severity have been seen based 366 on sex [56], and other groups that may benefit from vaccine prioritization include 367 healthcare workers (recommended in Vietnam [57]) and people with underlying health 368 conditions [58]. Additional simplifying assumptions were made regarding vaccine-induced 369 immunity. By having a single set of vaccine compartments, we assumed that all protection is 370 lost after vaccine immunity wanes, though immunity may wane only partially over time 371 [59,60]. We also assumed uniform vaccine effectiveness for all age groups. There is 372 evidence of lower vaccine effectiveness among elderly populations [61], though this finding 373 is not universal [62]; therefore, our analysis may be overestimating the benefits of vaccinating to elderly adults. 374

375

376 Few models exist for tropical influenza circulation with coexistence of distinct types and 377 subtypes [63]. As a result, we used a model with 50 parameterizations that reflect influenza 378 dynamics in Vietnam and can account for uncertainty in some parameters [25]. In our 379 analysis, prioritizing school-age children for annual influenza vaccination leads to the 380 greatest reductions in annual mortality in the implementation of a newly expanded vaccine 381 program. Characteristics of the vaccine, notably its average duration of inferred immunity 382 and efficacy, may impact how to allocate vaccines in a way that minimizes mortality, 383 particularly under low vaccine supplies. These findings are likely to be of interest to many 384 tropical countries that experience irregular timing of influenza epidemics and with plans to 385 increase currently low influenza vaccine coverage.

386

387 Methods and Materials

388

389 This study focuses on vaccine strategies in Vietnam, a LMIC with a population of 390 approximately 100 million. Vietnam has a subtropical climate in the northern half of the 391 country and a tropical climate in the southern half. Previous research has not identified 392 strong predictable cycles in influenza incidence for any (sub)type in any of northern, 393 central, or southern Vietnam [54]. Vietnam currently has low influenza vaccine coverage, 394 but there is interest in expanding coverage.

395

396 Mathematical model

397

398 Since only one known model exists that fits three co-circulating (sub)types of influenza in a 399 tropical region [63], we adapted our previous mathematical model, which was fit for a 400 single nonannual pathogen [54], to match the circulation patterns of multiple types and 401 subtypes of influenza, using fifty separate parameterizations for robustness. In our adapted 402 model, each (sub)type follows SIRS dynamics with a two-stage infected class and a four-403 stage recovered class [64]. (Figure S1, text S1). Periods of increased transmission occur 404 irregularly, with intervals between periods of increased transmission drawn stochastically 405 from a previously fit normal distribution of epidemic timings from ten years of sentinel 406 surveillance from fifteen hospitals located throughout Vietnam [54]. We incorporated 407 previously estimated levels of cross-immunity among (sub)types [63]. Single cases are 408 moved from the Susceptible class to an Infected class at regular intervals to represent case 409 importation. Hospitalization can occur during infection, using a hospitalization fraction 410 based on data from the US Centers for Disease Control and Prevention (CDC) [65]. Death 411 occurs from the hospital at a rate based on CDC data [65].

412

We divided the population into eight decade-based age groups, with the last group
consisting of adults 70 years and older, using published age demographics in Vietnam [66].
We incorporated a crude birth rate as reported by the World Bank [67] and an age-based
natural death rate as reported by the World Health Organization [68]. Age-based contact
mixing was incorporated in the model by using previously estimated age-based contact
patterns for Vietnam [69,70].

419

To ensure that our model allows all three (sub)types of influenza to co-circulate with
asynchronous behavior, we parameterized the model using known epidemiological
quantities in Vietnam such as annual attack rate and variance in timings between epidemic
peaks. Using a standard parameter-space search approach, we drew sets of parameters
from uniform distributions and retained 50 sets that produced model dynamics resembling
those seen in Vietnam, allowing asynchronous nonannual co-circulation of the three

426 (sub)types. Parameter values from literature are listed in Table S1 and full details of the427 parameter-space search can be found in Supplemental text S1.

428

429 Vaccine implementation

430

431 Our model allows vaccination from the Susceptible and Recovered compartments (Figure 432 S1). We applied vaccine strategies to the specified model, running the model for a 10-year 433 period and using average annual mortality over the ten years to compare effectiveness of 434 each. We organized our analyses around the central variable of vaccine supply and how best to allocate vaccines given supply constraints, considering supply relative to the population. 435 436 A 10% vaccine supply, therefore, is interpreted as having enough doses to vaccinate 10% of 437 the population. We considered vaccine supplies that cover 10% through 90% of the 438 population. The first vaccine strategies investigated whether administering vaccines during 439 a particular time of year would lead to the greatest reduction in average annual mortality. 440 In these scenarios, vaccines were assumed to be distributed proportionally across all age 441 groups within the population. We considered each calendar month as a starting point for 442 vaccine administration, and we considered vaccine administration durations of one through 443 four months. Additionally, we considered a scenario where vaccines are evenly distributed 444 to the population throughout the entire year.

445

The second set of vaccination scenarios considered prioritizing single age groups. For each
of the nine specified vaccine supplies, we considered prioritizing each age group by
vaccinating all members of that age group until 100% coverage is reached. The remaining
vaccines were then distributed to the remaining seven age groups proportionally to their
respective sizes.

451

The final set of vaccination scenarios considered ways to allocate all available doses across
all eight age groups rather than prioritizing one age group. In other words, we performed –
as completely as possible give computational limitations – a brute-force search over all
possible age-allocations. The purpose of this was to find previously unexamined optimal
ways to distribute or allocate available vaccines to the eight age groups. Full details of

457 developing these allocations can be found in supplemental text S2. Briefly, for each vaccine 458 supply, we sampled proportions (in [0, 1]) in each age group for an assigned vaccine 459 coverage and applied them to our model to evaluate mortality. We drew allocations, in the 460 form of sets of eight coverages, using Latin hypercube sampling, with (1) a rejection 461 mechanism for allocations that require major rescaling, and (2) an added constraint to 462 ensure that >95% coverages for individual age groups were achieved in the sampling. We 463 drew 10,000 allocations for supplies ranging between 10 and 60 percent of the population 464 and then 7500, 5000, and 2000 allocations for 70, 80, and 90 percent supplies, respectively, 465 since fewer feasible allocations exist at those high coverages. Each allocation was evaluated 466 for each of the 50 epidemiologically consistent parameter sets for Vietnam, and we 467 averaged the results across parameter sets for each allocation. We also considered an 468 allocation where doses are distributed proportionally to the relative sizes of age groups to 469 compare specific age-based vaccine allocations to naively distributing vaccines uniformly 470 throughout the entire population.

471

All analyses were run in R version 4.2.1 [71]. We used the 'Rcpp' package [72] for coding

and implementing the model, the 'lhs' package [73] for Latin Hypercube Sampling, and the

474 'parallel' package for computational efficiency.

475

477 Funding

478

- 479 This study was funded by the National Institutes of Health grant F32AI167600. The funders
- 480 had no role in the study design, data collection and analysis, decision to publish, or
- 481 preparation of the manuscript.
- 482
- 483

484 Data Availability

485

- 486 Data generated in this study and relevant code are available at
- 487 github.com/jlservadio/VN_Influenza_Vaccination

489 **References**

- Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. The Lancet.
 2018 Mar 31;391(10127):1285–300.
- 494 2. Heron M. Deaths: Leading Causes for 2019. Natl Vital Stat Rep [Internet]. 2021 Jul 26;70(9).
 495 Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr70/nvsr70-09-508.pdf
- 496 3. Choe YJ, Choe SA, Cho SI. Trends in Infectious Disease Mortality, South Korea, 1983–2015.
 497 Emerg Infect Dis. 2018 Feb;24(2):320–7.
- Johnson SC, Cunningham M, Dippenaar IN, Sharara F, Wool EE, Agesa KM, et al. Public
 health utility of cause of death data: applying empirical algorithms to improve data quality.
 BMC Med Inform Decis Mak. 2021 Jun 2;21(1):175.
- 5. World Health Organization. Global health estimates: Leading causes of death [Internet].
 [cited 2023 Jul 18]. Available from: https://www.who.int/data/gho/data/themes/mortalityand-global-health-estimates/ghe-leading-causes-of-death
- 6. Centers for Disease Control and Prevention. Flu Vaccination Coverage, United States, 2018–
 19 Influenza Season [Internet]. 2022 [cited 2023 Jul 18]. Available from: https://www.cdc.gov/flu/fluvaxview/coverage-1819estimates.htm
- Isenor JE, Alia TA, Killen JL, Billard BA, Halperin BA, Slayter KL, et al. Impact of pharmacists as
 immunizers on influenza vaccination coverage in Nova Scotia, Canada. Hum Vaccines
 Immunother. 2016 Feb 10;12(5):1225–8.
- Böhmer MM, Walter D, Müters S, Krause G, Wichmann O. Seasonal influenza vaccine uptake
 in Germany 2007/2008 and 2008/2009: results from a national health update survey.
 Vaccine. 2011 Jun 15;29(27):4492–8.
- Heins M, Hooiveld M, Korevaar J. Vaccine Coverage Dutch National Influenza Prevention
 Program 2020: brief monitor [Internet]. Utrecht: Nivel; 2021. Available from:
 https://www.nivel.nl/en/publicatie/vaccine-coverage-dutch-national-influenza-prevention program-2020-brief-monitor
- 517 10. Palache A, Abelin A, Hollingsworth R, Cracknell W, Jacobs C, Tsai T, et al. Survey of
 518 distribution of seasonal influenza vaccine doses in 201 countries (2004–2015): The 2003
 519 World Health Assembly resolution on seasonal influenza vaccination coverage and the 2009
 520 influenza pandemic have had very little impact on improving influenza control and
- 521 pandemic preparedness. Vaccine. 2017 Aug 24;35(36):4681–6.

11. Young B, Sadarangani S, Jiang L, Wilder-Smith A, Chen MIC. Duration of Influenza Vaccine
 Effectiveness: A Systematic Review, Meta-analysis, and Meta-regression of Test-Negative
 Design Case-Control Studies. J Infect Dis. 2018 Feb 14;217(5):731–41.

- Young BE, Chen M. Influenza in temperate and tropical Asia: a review of epidemiology and
 vaccinology. Hum Vaccines Immunother. 16(7):1659–67.
- 527 13. Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK, et al. Prevention
 528 and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory
 529 Committee on Immunization Practices United States, 2022–23 Influenza Season. MMWR
 530 Recomm Rep. 2022 Aug 26;71(1):1–28.
- 531 14. Gupta V, Dawood FS, Muangchana C, Lan PT, Xeuatvongsa A, Sovann L, et al. Influenza
 532 Vaccination Guidelines and Vaccine Sales in Southeast Asia: 2008–2011. PLOS ONE. 2012
 533 Dec 21;7(12):e52842.
- 534 15. Centers for Disease Control and Prevention. Flu Symptoms & Complications [Internet].
 535 Centers for Disease Control and Prevention. 2022 [cited 2023 Aug 3]. Available from:
 536 https://www.cdc.gov/flu/symptoms/symptoms.htm
- 537 16. Oakley S, Bouchet J, Costello P, Parker J. Influenza vaccine uptake among at-risk adults (aged
 538 16–64 years) in the UK: a retrospective database analysis. BMC Public Health. 2021 Sep
 539 24;21:1734.
- 540 17. Members of the Western Pacific Region Global Influenza Surveillance Response System,
 541 Dwyer D, Barr I, Hurt A, Kelso A, Reading P, et al. Seasonal influenza vaccine policies,
 542 recommendations and use in the World Health Organization's Western Pacific Region. West
 543 Pac Surveill Response J WPSAR. 2013;4(3):51–9.
- 18. Mertz D, Kim TH, Johnstone J, Lam PP, Science M, Kuster SP, et al. Populations at risk for
 severe or complicated influenza illness: systematic review and meta-analysis. The BMJ. 2013
 Aug 23;347:f5061.
- 547 19. World Health Organization. Global COVID-19 Vaccination Strategy in a Changing World: July
 548 2022 update [Internet]. 2022 [cited 2023 Aug 3]. Available from:
- 549 https://www.who.int/publications/m/item/global-covid-19-vaccination-strategy-in-a-550 changing-world--july-2022-update
- 20. Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, et al. Model-informed
 COVID-19 vaccine prioritization strategies by age and serostatus. Science. 2021 Feb
 26;371(6532):916–21.
- 21. Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese
 Experience with Vaccinating Schoolchildren against Influenza. N Engl J Med. 2001 Mar
 22;344(12):889–96.

557 22. Hill EM, Petrou S, Forster H, Lusignan S de, Yonova I, Keeling MJ. Optimising age coverage of 558 seasonal influenza vaccination in England: A mathematical and health economic evaluation.

- 559 PLOS Comput Biol. 2020 Oct 6;16(10):e1008278.
- 23. Longini IM Jr, Halloran ME. Strategy for Distribution of Influenza Vaccine to High-Risk Groups
 and Children. Am J Epidemiol. 2005 Feb 15;161(4):303–6.
- 562 24. Medlock J, Galvani AP. Optimizing Influenza Vaccine Distribution. Science. 2009 Sep
 563 25;325(5948):1705–8.
- S64 25. Ndeffo Mbah ML, Medlock J, Meyers LA, Galvani AP, Townsend JP. Optimal targeting of
 seasonal influenza vaccination toward younger ages is robust to parameter uncertainty.
 Vaccine. 2013 Jun 26;31(30):3079–89.
- 567 26. Goldstein E, Apolloni A, Lewis B, Miller JC, Macauley M, Eubank S, et al. Distribution of
 568 vaccine/antivirals and the 'least spread line' in a stratified population. J R Soc Interface.
 569 2010 May 6;7(46):755–64.
- 570 27. Miller MA, Viboud C, Olson DR, Grais RF, Rabaa MA, Simonsen L. Prioritization of Influenza
 571 Pandemic Vaccination to Minimize Years of Life Lost. J Infect Dis. 2008 Aug 1;198(3):305–11.
- 572 28. Knipl DH, Röst G. Modelling the strategies for age specific vaccination scheduling during
 573 influenza pandemic outbreaks. Math Biosci Eng MBE. 2011 Jan;8(1):123–39.
- 574 29. Mylius SD, Hagenaars TJ, Lugnér AK, Wallinga J. Optimal allocation of pandemic influenza
 575 vaccine depends on age, risk and timing. Vaccine. 2008 Jul 4;26(29–30):3742–9.
- 30. Bansal S, Pourbohloul B, Meyers LA. A Comparative Analysis of Influenza Vaccination
 Programs. PLOS Med. 2006 Oct 3;3(10):e387.
- 578 31. Centers for Disease Control and Prevention. Past Seasons' Vaccine Effectiveness (VE)
 579 Estimates [Internet]. Centers for Disease Control and Prevention. 2023 [cited 2023 Aug 3].
 580 Available from: https://www.cdc.gov/flu/vaccines-work/past-seasons-estimates.html
- 32. Ferdinands JM, Gaglani M, Martin ET, Middleton D, Monto AS, Murthy K, et al. Prevention of
 Influenza Hospitalization Among Adults in the United States, 2015-2016: Results From the
 US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). J Infect Dis. 2019
 Sep 13;220(8):1265–75.
- 33. Institute for Environmental Science and Research Limited. 2019 Annual Influenza Summary
 [Internet]. Available from: https://www.esr.cri.nz/assets/Intelligence-Hub 2023/Surveillance-reports-and-dashboards/Influenza/InfluenzaAnn2019.pdf
- 34. Cheng AC, Dwyer DE, Homes M, Irving LB, Brown SG, Waterer GW, et al. Influenza
 epidemiology, vaccine coverage and vaccine effectiveness in sentinel Australian hospitals in
 2013: the Influenza Complications Alert Network [Internet]. Australian Government

- 591 Department of Health; [cited 2023 Aug 3]. Available from:
- 592 https://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-cdi3802e.htm
- 35. Arriola C, Garg S, Anderson EJ, Ryan PA, George A, Zansky SM, et al. Influenza Vaccination
 Modifies Disease Severity Among Community-dwelling Adults Hospitalized With Influenza.
 Clin Infect Dis Off Publ Infect Dis Soc Am. 2017 Oct 15;65(8):1289–97.
- 36. Doyon-Plourde P, Przepiorkowski J, Young K, Zhao L, Sinilaite A. Intraseasonal waning
 immunity of seasonal influenza vaccine A systematic review and meta-analysis. Vaccine.
 2023 Jul 12;41(31):4462–71.
- 37. Weycker D, Edelsberg J, Halloran ME, Longini IM, Nizam A, Ciuryla V, et al. Population-wide
 benefits of routine vaccination of children against influenza. Vaccine. 2005 Jan
 26;23(10):1284–93.
- 38. Wallinga J, Teunis P, Kretzschmar M. Using data on social contacts to estimate age-specific
 transmission parameters for respiratory-spread infectious agents. Am J Epidemiol. 2006 Nov
 15;164(10):936–44.
- 39. Halloran ME, Longini IM. Community Studies for Vaccinating Schoolchildren Against
 Influenza. Science. 2006 Feb 3;311(5761):615–6.
- 40. Quandelacy TM, Viboud C, Charu V, Lipsitch M, Goldstein E. Age- and Sex-related Risk
 Factors for Influenza-associated Mortality in the United States Between 1997–2007. Am J
 Epidemiol. 2014 Jan 15;179(2):156–67.
- 41. Li L, Yan ZL, Luo L, Liu W, Yang Z, Shi C, et al. Influenza-Associated Excess Mortality by Age,
 Sex, and Subtype/Lineage: Population-Based Time-Series Study With a Distributed-Lag
 Nonlinear Model. JMIR Public Health Surveill. 2023 Jan 11;9:e42530.
- 42. Tokars JI, Olsen SJ, Reed C. Seasonal Incidence of Symptomatic Influenza in the United
 States. Clin Infect Dis Off Publ Infect Dis Soc Am. 2018 May 2;66(10):1511–8.
- 43. World Health Organization. Vaccines against influenza: WHO position paper May 2022.
 Wkly Epidemiol Rec. 2022 May 13;97(19):185–208.
- 44. Newall AT, Dehollain JP. The cost-effectiveness of influenza vaccination in elderly Australians:
 an exploratory analysis of the vaccine efficacy required. Vaccine. 2014 Mar 10;32(12):1323–
 5.
- 45. Schwartz B, Orenstein WA. Prioritization of Pandemic Influenza Vaccine: Rationale and
 Strategy for Decision Making. Vaccines Pandemic Influenza. 2009 Jun 15;333:495–507.
- 46. Tran TNA, Wikle NB, Albert E, Inam H, Strong E, Brinda K, et al. Optimal SARS-CoV-2 vaccine
 allocation using real-time attack-rate estimates in Rhode Island and Massachusetts. BMC
 Med. 2021 Jul 13;19(1):162.

- 47. Worby CJ, Chaves SS, Wallinga J, Lipsitch M, Finelli L, Goldstein E. On the relative role of
 different age groups in influenza epidemics. Epidemics. 2015 Dec;13:10–6.
- 48. Schmid P, Rauber D, Betsch C, Lidolt G, Denker ML. Barriers of Influenza Vaccination
 Intention and Behavior A Systematic Review of Influenza Vaccine Hesitancy, 2005 2016.
 PloS One. 2017;12(1):e0170550.
- 49. Price T, McColl E, Visram S. Barriers and facilitators of childhood flu vaccination: the views of
 parents in North East England. Z Gesundheitswissenschaften J Public Health.
 2022;30(11):2619–26.
- 50. Basta NE, Chao DL, Halloran ME, Matrajt L, Longini IM. Strategies for pandemic and seasonal
 influenza vaccination of schoolchildren in the United States. Am J Epidemiol. 2009 Sep
 15;170(6):679–86.
- 51. Plans-Rubió P. The vaccination coverage required to establish herd immunity against
 influenza viruses. Prev Med. 2012 Jul;55(1):72–7.
- 52. Sah P, Medlock J, Fitzpatrick MC, Singer BH, Galvani AP. Optimizing the impact of lowefficacy influenza vaccines. Proc Natl Acad Sci U S A. 2018 May 15;115(20):5151–6.
- 53. Patel R, Longini IM, Halloran ME. Finding optimal vaccination strategies for pandemic
 influenza using genetic algorithms. J Theor Biol. 2005 May 21;234(2):201–12.
- 54. Servadio JL, Thai PQ, Choisy M, Boni MF. Repeatability and timing of tropical influenza
 epidemics. PLOS Comput Biol. 2023 Jul 19;19(7):e1011317.
- 55. Bennett KJ, Pumkam C, Probst JC. Rural-urban differences in the location of influenza
 vaccine administration. Vaccine. 2011 Aug 11;29(35):5970–7.
- 56. vom Steeg LG, Klein SL. SeXX Matters in Infectious Disease Pathogenesis. PLoS Pathog. 2016
 Feb 18;12(2):e1005374.
- 57. Ha NT, Nguyen TTM, Nguyen TX, Tran PD, Nguyen HM, Ha VT, et al. A case study of an
 influenza vaccination program for health care workers in Vietnam. BMC Health Serv Res.
 2020 Aug 24;20(1):785.
- 58. Baguelin M, Jit M, Miller E, Edmunds WJ. Health and economic impact of the seasonal
 influenza vaccination programme in England. Vaccine. 2012 May 14;30(23):3459–62.
- 59. Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J, VanWormer JJ. Waning
 vaccine protection against influenza A (H3N2) illness in children and older adults during a
 single season. Vaccine. 2015 Jan 1;33(1):246–51.

- 60. Ray GT, Lewis N, Klein NP, Daley MF, Wang SV, Kulldorff M, et al. Intraseason Waning of
 Influenza Vaccine Effectiveness. Clin Infect Dis Off Publ Infect Dis Soc Am. 2019 May
 2;68(10):1623–30.
- 61. Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Osterholm MT, et al. Variable
 influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of testnegative design studies. Lancet Infect Dis. 2016 Aug 1;16(8):942–51.
- 62. Russell K, Chung JR, Monto AS, Martin ET, Belongia EA, McLean HQ, et al. Influenza Vaccine
 63 Effectiveness in Older Adults Compared with Younger Adults Over Five Seasons. Vaccine.
 664 2018 Feb 28;36(10):1272–8.
- 665 63. Yang W, Lau EHY, Cowling BJ. Dynamic interactions of influenza viruses in Hong Kong during 666 1998-2018. PLoS Comput Biol. 2020 Jun 15;16(6).
- 667 64. Lloyd AL. Realistic Distributions of Infectious Periods in Epidemic Models: Changing Patterns
 668 of Persistence and Dynamics. Theor Popul Biol. 2001 Aug 1;60(1):59–71.
- 669 65. Centers for Disease Control and Prevention. Estimated Flu-Related Illnesses, Medical visits,
 670 Hospitalizations, and Deaths in the United States 2018–2019 Flu Season [Internet]. 2021
 671 [cited 2023 Aug 3]. Available from: https://www.cdc.gov/flu/about/burden/2018-2019.html
- 66. Vietnam Population 2023 [Internet]. World Population Review. [cited 2023 Aug 3]. Available
 from: https://worldpopulationreview.com/countries/vietnam-population
- 674 67. World Bank. Birth rate, crude (per 1,000 people) Vietnam [Internet]. World Bank Open
- Data. [cited 2023 Sep 12]. Available from:
- 676 https://data.worldbank.org/indicator/SP.DYN.CBRT.IN?locations=VN
- 677 68. World Health Organization. Life tables: Life tables by country Viet Nam [Internet]. Regional
 678 Health Observatory South East Asia. 2020 [cited 2023 Sep 7]. Available from:
 679 https://apps.who.int/gho/data/view.searo.61830?lang=en
- 680 69. Prem K, Zandvoort K van, Klepac P, Eggo RM, Davies NG, Group C for the MM of IDC 19 W, et
 681 al. Projecting contact matrices in 177 geographical regions: An update and comparison with
 682 empirical data for the COVID-19 era. PLOS Comput Biol. 2021 Jul 26;17(7):e1009098.
- 70. Prem K. kieshaprem/synthetic-contact-matrices: First release of the synthetic contact
 matrices repository [Internet]. Zenodo; 2021 [cited 2023 Sep 13]. Available from:
 https://zenodo.org/record/4889500
- 71. R Core Team. R: A language and environment for statistical computing [Internet]. Vienna,
 Austria: R Foundation for Statistical Computing; 2022. Available from: https://www.Rproject.org

- 689 72. Eddelbuettel D, Francois R. Rcpp: Seamless R and C++ Integration. J Stat Softw. 2011 Apr
 690 13;40:1–18.
- 691 73. Carnell R. Ihs: Latin Hypercube Samples [Internet]. 2022. Available from: https://CRAN.R 692 project.org/package=lhs
- 693
- 694